ERBB2 and neoplasm: Seventy of 80 patients in the training set had a change in chemotherapy regimen between T1 and T2; 3 tumor subtypes (HR+Her2+, HR-Her2+, HR-Her2-) were represented within the patient group that did not have a change in drug regimen.